1. Scrip
  2. >>New Products

Sanofi/AstraZeneca Win Beyfortus Approval To Prevent RSV In US Infants

Prophylactic Antibody A Key Asset In Sanofi’s Vaccine Portfolio

 
• By Mandy Jackson

Sanofi, which leads commercialization under its 2017 deal with AstraZeneca, may soon compete with a maternal RSV vaccine from Pfizer, but the US may have room for only one infant-protecting option.

Portrait of asian parent hands holding newborn baby
Beyfortus is approved for newborns and toddlers in their second RSV season • Source: Shutterstock

Sanofi received an important win in the US on 17 July when the US Food and Drug Administration approved the AstraZeneca PLC-partnered antibody Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) in infants, a key market for one of prime products in the French big pharma’s push to turn its €3bn vaccines portfolio into a €10bn ($10.9bn) business by 2030. However, a Beyfortus challenger that could still garner significant US market share is awaiting approval next month.

Pfizer Inc.’s RSV vaccine Abrysvo was approved for older adults in June shortly after the FDA approved GSK...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.